

## Accomplishments

### Dr. Priya Ramanathan

Dr. Priya was involved in the generation, characterization, and phase I trial of DC vaccines and worked on the establishment of QC criteria for DC vaccine efficacy. Subsequently is working on two Phase II trials involving DC vaccines for cervical cancer and ovarian cancer. She has also been working on a study to understand the role of immune dysfunction in the cervical tumor. Currently she has received approval for a SERB-DST funded project which aims to improve DC vaccine efficacy.

### Key Publications:

1. **Priya Ramanathan**, Selvaluxmy Ganeshrajah, Rajalekshmi Kamalalayam Raghanvan, Shirley Sunder Singh, and Rajkumar Thangarajan. "Development and Clinical Evaluation of Dendritic Cell Vaccines for HPV Related Cervical Cancer-a Feasibility Study." Asian Pacific journal of cancer prevention: APJCP 15, no. 14 (2013): 5909-5916.
2. Hascitha, J., **Priya, R.**, Jayavelu, S., Dhandapani, H., Selvaluxmy, G., Singh, S. S., & Rajkumar, T. (2016). Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients. Clinical biochemistry. 2016 Aug 1;49 (12):919-24.
3. Dhandapani H, Seetharaman A, Jayakumar H, Ganeshrajah S, Singh SS, Thangarajan R, **Ramanathan P.\*** Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro. J Gynecol Oncol. 2021;32:e59.
4. Hemavathi Dhandapani, Hascitha Jayakumar, Abirami Seetharaman, Shirley Sunder Singh, Selvaluxmy Ganeshrajah, Nirmala Jagadish, Anil Suri, Rajkumar Thangarajan, **Priya Ramanathan\***. Dendritic cells matured with recombinant human sperm associated antigen 9 (rhSPAG9) induce CD4+, CD8+ T cells and activate NK cells: a potential candidate molecule for immunotherapy in cervical cancer. Cancer Cell Int 21, 473 (2021).
5. Hascitha Jayakumar, Abirami Seetharaman, Shirley Sunder Singh, Hemavathi Dhandapani, Jayavelu Subramani, Selvaluxmy Ganeshrajah, Rajkumar Thangarajan, **Priya Ramanathan\***, Combination of IDO1high and CCL19low expression in the tumor tissue reduces survival in HPV positive cervical cancer, Journal of Reproductive Immunology, 2021,ISSN 0165-0378

\*Corresponding author

Google scholar links: <https://scholar.google.com/citations?user=wAskp-wAAAAJ&hl=en>